Pharmaceutical Technology reports on NVIDIA’s endorsement of the Innophore partnership for modelling drug dynamics with AI. Innophore’s CavitOmiX platform uses deep learning to screen for new drug candidates, predict hidden side effects, and identify repurposing opportunities for existing molecules. The technology analyzes protein cavities independently of sequence or fold, enabling a ligand-agnostic approach to off-target prediction that could fundamentally change early-stage drug safety assessment.

Read the full article at Pharmaceutical Technology